Skip to content
Bored Studies
RecruitingPhase 3

Efficacy, Safety and Tolerability of Switching From Glucagon-like Peptide-1 Receptor Agonists (GLP-1RA) to Maridebart Cafraglutide in Adults With Obesity or Overweight (MARITIME-SWITCH)

Amgen · NCT07575399

View Study & Apply (opens in a new tab)

Opens the official ClinicalTrials.gov record, with the study team’s contacts. Bored Studies doesn’t enroll anyone.

Key facts

Compensation
Not posted. Ask the study team before screening.
Who can join
Ages 18–99 · All sexes
Healthy volunteers
Not accepted (a condition is required)
Study type
Interventional · Phase 3
Target enrollment
300
US sites recruiting
52
Study start
May 11, 2026
Record last updated
October 23, 2026

Status re-checked against ClinicalTrials.gov within the last 12 hours.

What the study is about

Efficacy, safety and tolerability of switching from GLP-1RA to maridebart cafraglutide in adults with obesity or overweight.

Being studied: Maridebart Cafraglutide

Conditions: Obesity or Overweight

Eligibility criteria

Copied from the official record. The study team makes the final decision at screening.

Show full criteria

Inclusion Criteria

  • Body Mass Index (BMI) ≥ 25 at screening.
  • Weight loss of ≥ 10% on weekly GLP-1 RA.
  • Stable body weight.
  • Stable dose of GLP-1RA.
  • Stable gastrointestinal (GI) tolerability.
  • Contraception for females.
  • Willingness to follow trial procedures for the duration of the trial.

Exclusion Criteria

  • Obesity induced by other endocrine disorders (ex: Cushing's syndrome).
  • Previous or planned surgical, endoscopic or device-based treatment for obesity.
  • History of malignancy.
  • Type 1/Type 2 diabetes mellitus (DM).
  • Family or personal history of medullary thyroid cancer.
  • Previous participation in a Maridebart Cafraglutide trial.

Recruiting US locations

Study contacts (from the official record)

  • Amgen Call Center · 866-572-6436 · medinfo@amgen.com
All weight loss studies in Alabama →
Efficacy, Safety and Tolerability of Switching From Glucagon-like… (NCT07575399) | Bored Studies